Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.
Adeline
A
Gallini
Agnès
A
Sommet
Anne-Marie
AM
Salandini
Patrick
P
Veyssière
Jean-Louis
JL
Montastruc
Jean-Louis
JL
Montastruc
D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005702:Galantamine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D020961:Lewy Body Disease / Q000188:drug therapy*; D008559:Memantine / Q000009:adverse effects* / Q000627:therapeutic use; D008609:Mental Status Schedule; D009325:Nausea / Q000139:chemically induced; D018697:Nootropic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced; D015431:Weight Loss / Q000187:drug effects*
D000978:Antiparkinson Agents; D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents; D005702:Galantamine; D008559:Memantine